MDMA

The MDMA Conference: A Molecular Masterclass Presents a Scientific Deep Dive into the Field of MDMA Therapeutics

Monday, June 14, 2021 - 2:35pm

Ranging from exploring the cultural implications of MDMA through to its clinical applications, the conference will seek to educate attendees on the potential uses and benefits attached to MDMA in a clinical environment.

Key Points: 
  • Ranging from exploring the cultural implications of MDMA through to its clinical applications, the conference will seek to educate attendees on the potential uses and benefits attached to MDMA in a clinical environment.
  • The event, which will present a scientific deep dive into the dynamic field of MDMA therapeutics, will explore the potential of MDMA at the intersection of drug development & safety, clinical care and applications, law & regulation, business & markets, science & research as well as history & culture.
  • This years event will feature a series of six keynote presentations and discussion panels, to be held over the course of the one-day event.
  • Additional information about the MDMA Conference, as well as details for registration, can be found on the MDMA Conference website at https://microdose.buzz/shop/molecular-masterclass/mdma-conference/ .

Awakn Life Sciences to Participate in the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference

Thursday, June 10, 2021 - 1:00pm

Toronto, Ontario--(Newsfile Corp. - June 10, 2021) - Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, and Professor Celia Morgan, Head of Awakn's Ketamine-Assisted Psychotherapy for Addiction Practice, will participate in H.C. Wainwright's Psychedelics in Psychiatry and Beyond Virtual Conference panels on Thursday, June 17, 2021.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - June 10, 2021) - Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, and Professor Celia Morgan, Head of Awakn's Ketamine-Assisted Psychotherapy for Addiction Practice, will participate in H.C. Wainwright's Psychedelics in Psychiatry and Beyond Virtual Conference panels on Thursday, June 17, 2021.
  • For more information regarding the conference, or to schedule a one-on-one meeting with Awakn's management team, please contact KCSA Strategic Communications at Awakn@KCSA.com or your H.C. Wainwright representatives directly.
  • About Awakn Life Sciences Inc.
    Awakn Life Sciences is a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat Addiction.
  • Awakn is integrating psychedelic medicine into mainstream healthcare through Research, Digital, Clinics, and Ecosystems.

2021 Global Methylamine Hydrobromide (CAS 6876-37-5) Market Research Report - Downstream Industry Trends - ResearchAndMarkets.com

Tuesday, June 8, 2021 - 3:09pm

The "Methylamine hydrobromide (CAS 6876-37-5) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Methylamine hydrobromide (CAS 6876-37-5) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Methylamine hydrobromide.
  • The Methylamine hydrobromide global market report key points:
    The first chapter introduces the product (composition, structure, hazards, storage, toxicological & ecological information, etc.).
  • The fifth chapter deals with Methylamine hydrobromide market trends and forecast, distinguish Methylamine hydrobromide manufacturers and suppliers.

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Wednesday, May 19, 2021 - 1:03pm

With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases.

Key Points: 
  • With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases.
  • Catalyst\'s New Drug Application for Firdapse\xc2\xae (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in 2018 by the\xc2\xa0U.S.
  • Copies of Catalyst\'s filings with the SEC are available from the SEC, may be found on Catalyst\'s website, or may be obtained upon request from Catalyst.
  • Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.\n'

Microdose is Pleased to Announce The MDMA Conference: A Molecular Masterclass -- and We're Calling for Speakers

Monday, May 17, 2021 - 4:16pm

b"If you feel that your expertise and experience positions you as a thought-leader in the space, we invite you to complete the application to become a speaker at this cutting-edge event.\nMicrodose conferences are highly regarded by market leaders across the psychedelic sector, thanks to our consistently strong and well-respected speakers and content guidance.

Key Points: 
  • b"If you feel that your expertise and experience positions you as a thought-leader in the space, we invite you to complete the application to become a speaker at this cutting-edge event.\nMicrodose conferences are highly regarded by market leaders across the psychedelic sector, thanks to our consistently strong and well-respected speakers and content guidance.
  • As a speaker at one of Microdose's events, you will have the opportunity to give an expert presentation, and network with other key participants and new entrants in the field.\n- Receive visibility in pre-event, and post-event marketing materials, including social media, direct event promotion, email newsletters, and promotional partners\n* To be considered for a speaking slot, complete the form below.
  • Speaker selections will be made by the selection team and notifications will go out to all those that are chosen to speak via email.\n* Please submit only thorough topic presentations and demonstration of expertise.\n* Presentations should last between 30-60 minutes overall (depending on the topic and structure of the session), including Q&A from the audience.
  • You must be an expert on the subject and be able to converse fluently in an organic manner.\n* We are looking for a diverse lineup of speakers including both those who have spoken at psychedelics events in the past and those who have not, speakers covering a diverse range of geographic areas, those who are at different stages of their company evolution, and speakers who have not spoken recently or ever at one of our conferences as we strive to increase diversity and inclusion in all of our event productions.\nIf you are interested in learning about sponsorship opportunities for The MDMA Conference, reach out to kristina@microdose.buzz for details.\nTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/83672\n"

Psychedelics Move to The Forefront of Innovative Research as the FDA Approves Large-Scale Testing

Thursday, May 13, 2021 - 1:50pm

The FDA recently approved large-scale human trials to determine whether MDMA and other psychedelics warrant the agency\'s approval for treatment.

Key Points: 
  • The FDA recently approved large-scale human trials to determine whether MDMA and other psychedelics warrant the agency\'s approval for treatment.
  • The result is a budding industry of psychedelic research and innovation that is quickly moving these alternative treatments to the forefront of the medical community\'s attention.
  • For companies like Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF), psychedelics are the lynchpin of a strategy to treat the rare and difficult diseases that currently have unmet needs.
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

Psychedelics Move to The Forefront of Innovative Research as the FDA Approves Large-Scale Testing

Thursday, May 13, 2021 - 1:50pm

The FDA recently approved large-scale human trials to determine whether MDMA and other psychedelics warrant the agency\'s approval for treatment.

Key Points: 
  • The FDA recently approved large-scale human trials to determine whether MDMA and other psychedelics warrant the agency\'s approval for treatment.
  • The result is a budding industry of psychedelic research and innovation that is quickly moving these alternative treatments to the forefront of the medical community\'s attention.
  • For companies like Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF), psychedelics are the lynchpin of a strategy to treat the rare and difficult diseases that currently have unmet needs.
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

MindMed Announces the Publication of New Data on Personalized MDMA Dosing

Monday, April 5, 2021 - 12:30pm

This study provides the first scientific data for predicting responses to MDMA and optimizing dosing.

Key Points: 
  • This study provides the first scientific data for predicting responses to MDMA and optimizing dosing.
  • Women and men showed comparable MDMA effects if differences in body weight are considered in the dosing of MDMA.
  • Previous minimal MDMA use, defined as previously using MDMA up to five times, did not influence the MDMA effect.
  • In summary, personalizing MDMA dosing may help optimizethe acute MDMA experience including more positive subjective effects of MDMA and reducing adverse effects of MDMA.

Global Serotonin Creatinine Sulfate (CAS 61-47-2) Market Research Report 2021 - ResearchAndMarkets.com

Thursday, April 1, 2021 - 4:46pm

The "Serotonin creatinine sulfate (CAS 61-47-2) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Serotonin creatinine sulfate (CAS 61-47-2) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Serotonin creatinine sulfate.
  • The fifth chapter deals with Serotonin creatinine sulfate market trends and forecast, distinguish Serotonin creatinine sulfate manufacturers and suppliers.
  • The Serotonin creatinine sulfate global market report key points:

Why Mainstream Mental-Health Care is Embracing Psilocybin - Alternative Active Substances

Wednesday, March 31, 2021 - 1:30pm

While the study of psychedelics as medicine, all across the globe, is inching toward the mainstream, it still remains somewhat controversial.

Key Points: 
  • While the study of psychedelics as medicine, all across the globe, is inching toward the mainstream, it still remains somewhat controversial.
  • A recent article on WIRED (UK) projected that Psychedelic medicine will begin to cross over into the mental health mainstream in 2021.
  • "In both Europe and the US, medicines regulators have eased restrictions on using MDMA to treat post-traumatic disorder (PTSD), and on psilocybin the active substance in magic mushrooms to treat depression.
  • In the UK, London-based mental-health care company COMPASS Pathways has raised more than $115m to fund its efforts and bring to market a psilocybin treatment for depression.